Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-6.

Vanden Eynde JJ, Mangoni AA, Rautio J, Leprince J, Azuma YT, García-Sosa AT, Hulme C, Jampilek J, Karaman R, Li W, Gomes PAC, Hadjipavlou-Litina D, Capasso R, Geronikaki A, Cerchia L, Sabatier JM, Ragno R, Tuccinardi T, Trabocchi A, Winum JY, Luque FJ, Prokai-Tatrai K, Spetea M, Gütschow M, Kosalec I, Guillou C, Vasconcelos MH, Kokotos G, Rastelli G, de Sousa ME, Manera C, Gemma S, Mangani S, Siciliano C, Galdiero S, Liu H, Scott PJH, de Los Ríos C, Agrofoglio LA, Collina S, Guedes RC, Muñoz-Torrero D.

Molecules. 2019 Dec 28;25(1). pii: E119. doi: 10.3390/molecules25010119.

2.

Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice.

Moya IM, Castaldo SA, Van den Mooter L, Soheily S, Sansores-Garcia L, Jacobs J, Mannaerts I, Xie J, Verboven E, Hillen H, Algueró-Nadal A, Karaman R, Van Haele M, Kowalczyk W, De Waegeneer M, Verhulst S, Karras P, van Huffel L, Zender L, Marine JC, Roskams T, Johnson R, Aerts S, van Grunsven LA, Halder G.

Science. 2019 Nov 22;366(6468):1029-1034. doi: 10.1126/science.aaw9886.

PMID:
31754005
3.

The Biological Activity of Natural Alkaloids against Herbivores, Cancerous Cells and Pathogens.

Thawabteh A, Juma S, Bader M, Karaman D, Scrano L, Bufo SA, Karaman R.

Toxins (Basel). 2019 Nov 11;11(11). pii: E656. doi: 10.3390/toxins11110656. Review.

4.

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-5.

Mangoni AA, Eynde JJV, Jampilek J, Hadjipavlou-Litina D, Liu H, Reynisson J, Sousa ME, Gomes PAC, Prokai-Tatrai K, Tuccinardi T, Sabatier JM, Luque FJ, Rautio J, Karaman R, Vasconcelos MH, Gemma S, Galdiero S, Hulme C, Collina S, Gütschow M, Kokotos G, Siciliano C, Capasso R, Agrofoglio LA, Ragno R, Muñoz-Torrero D.

Molecules. 2019 Jun 30;24(13). pii: E2415. doi: 10.3390/molecules24132415.

5.

YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.

Van Haele M, Moya IM, Karaman R, Rens G, Snoeck J, Govaere O, Nevens F, Verslype C, Topal B, Monbaliu D, Halder G, Roskams T.

Int J Mol Sci. 2019 Feb 1;20(3). pii: E638. doi: 10.3390/ijms20030638.

6.

Successes, failures, and future prospects of prodrugs and their clinical impact.

Najjar A, Karaman R.

Expert Opin Drug Discov. 2019 Mar;14(3):199-220. doi: 10.1080/17460441.2019.1567487. Epub 2019 Feb 4.

PMID:
30714428
7.

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes⁻4.

Mangoni AA, Guillou C, Vanden Eynde JJ, Hulme C, Jampilek J, Li W, Prokai-Tatrai K, Rautio J, Collina S, Tuccinardi T, Sousa ME, Sabatier JM, Galdiero S, Karaman R, Kokotos G, Torri G, Luque FJ, Vasconcelos MH, Hadjipavlou-Litina D, Siciliano C, Gütschow M, Ragno R, Gomes PAC, Agrofoglio LA, Muñoz-Torrero D.

Molecules. 2018 Dec 31;24(1). pii: E130. doi: 10.3390/molecules24010130.

8.

The prodrug approach in the era of drug design.

Najjar A, Karaman R.

Expert Opin Drug Deliv. 2019 Jan;16(1):1-5. doi: 10.1080/17425247.2019.1553954. Epub 2018 Dec 18. No abstract available.

PMID:
30558447
9.

RENIN-SECRETING OVARIAN ADULT GRANULOSA CELL TUMOR IN A PATIENT WITH NEW-ONSET HYPERTENSION AND HYPOKALEMIA.

Karaman R, Xu J, Harrison RF, Kushner DM, Weisman PS, Shenker Y.

AACE Clin Case Rep. 2018 Nov 1;5(2):e168-e171. doi: 10.4158/ACCR-2018-0355. eCollection 2019 Mar-Apr.

10.

Bitterless guaifenesin prodrugs-design, synthesis, characterization, in vitro kinetics, and bitterness studies.

Thawabteh A, Lelario F, Scrano L, Bufo SA, Nowak S, Behrens M, Di Pizio A, Niv MY, Karaman R.

Chem Biol Drug Des. 2019 Mar;93(3):262-271. doi: 10.1111/cbdd.13409. Epub 2018 Nov 2.

PMID:
30276968
11.

Photodegradation using TiO2-activated borosilicate tubes.

Khalaf S, Shoqeir JH, Scrano L, Karaman R, Bufo SA.

Environ Sci Pollut Res Int. 2019 Jul;26(19):19025-19034. doi: 10.1007/s11356-018-2858-5. Epub 2018 Aug 16.

PMID:
30117024
12.

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-3.

Mangoni AA, Tuccinardi T, Collina S, Vanden Eynde JJ, Muñoz-Torrero D, Karaman R, Siciliano C, de Sousa ME, Prokai-Tatrai K, Rautio J, Guillou C, Gütschow M, Galdiero S, Liu H, Agrofoglio LA, Sabatier JM, Hulme C, Kokotos G, You Q, Gomes PAC.

Molecules. 2018 Jun 30;23(7). pii: E1596. doi: 10.3390/molecules23071596. No abstract available.

13.

Strategies for Enhancing the Permeation of CNS-Active Drugs through the Blood-Brain Barrier: A Review.

Zeiadeh I, Najjar A, Karaman R.

Molecules. 2018 May 28;23(6). pii: E1289. doi: 10.3390/molecules23061289. Review.

14.

Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease.

Haddad F, Sawalha M, Khawaja Y, Najjar A, Karaman R.

Molecules. 2017 Dec 25;23(1). pii: E40. doi: 10.3390/molecules23010040. Review.

15.

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-2.

Muñoz-Torrero D, Mangoni AA, Liu H, Hulme C, Rautio J, Karaman R, de Sousa ME, Prokai-Tatrai K, Sabatier JM, Siciliano C, Luque FJ, Kokotos G, Ragno R, Collina S, Guillou C, Gütschow M, Agrofoglio LA.

Molecules. 2017 Dec 28;23(1). pii: E65. doi: 10.3390/molecules23010065.

16.

Advanced Prodrug Strategies in Nucleoside and Non-Nucleoside Antiviral Agents: A Review of the Recent Five Years.

Sinokrot H, Smerat T, Najjar A, Karaman R.

Molecules. 2017 Oct 16;22(10). pii: E1736. doi: 10.3390/molecules22101736. Review.

17.

Cell Junctions in Hippo Signaling.

Karaman R, Halder G.

Cold Spring Harb Perspect Biol. 2018 May 1;10(5). pii: a028753. doi: 10.1101/cshperspect.a028753. Review.

PMID:
28600393
18.

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes.

Muñoz-Torrero D, Mangoni AA, Guillou C, Collina S, Vanden Eynde JJ, Rautio J, Keserű GM, Hulme C, Chibale K, Luque FJ, Karaman R, Gütschow M, Liu H, Ragno R.

Molecules. 2017 May 5;22(5). pii: E743. doi: 10.3390/molecules22050743.

19.

Recent Approaches to Platinum(IV) Prodrugs: A Variety of Strategies for Enhanced Delivery and Efficacy.

Najjar A, Rajabi N, Karaman R.

Curr Pharm Des. 2017;23(16):2366-2376. doi: 10.2174/1381612823666170201161037. Review.

PMID:
28155621
20.

Comparing Class A GPCRs to bitter taste receptors: Structural motifs, ligand interactions and agonist-to-antagonist ratios.

Di Pizio A, Levit A, Slutzki M, Behrens M, Karaman R, Niv MY.

Methods Cell Biol. 2016;132:401-27. doi: 10.1016/bs.mcb.2015.10.005. Epub 2015 Dec 24.

PMID:
26928553
21.

Paracetamol biodegradation by activated sludge and photocatalysis and its removal by a micelle-clay complex, activated charcoal, and reverse osmosis membranes.

Karaman R, Khamis M, Abbadi J, Amro A, Qurie M, Ayyad I, Ayyash F, Hamarsheh O, Yaqmour R, Nir S, Bufo SA, Scrano L, Lerman S, Gur-Reznik S, Dosoretz CG.

Environ Technol. 2016 Oct;37(19):2414-27. doi: 10.1080/09593330.2016.1150355. Epub 2016 Mar 7.

PMID:
26852629
22.

Probing the Binding Pocket of the Broadly Tuned Human Bitter Taste Receptor TAS2R14 by Chemical Modification of Cognate Agonists.

Karaman R, Nowak S, Di Pizio A, Kitaneh H, Abu-Jaish A, Meyerhof W, Niv MY, Behrens M.

Chem Biol Drug Des. 2016 Jul;88(1):66-75. doi: 10.1111/cbdd.12734. Epub 2016 Feb 17.

PMID:
26825540
23.

Recent updates in utilizing prodrugs in drug delivery (2013-2015).

Amly W, Karaman R.

Expert Opin Drug Deliv. 2016;13(4):571-91. doi: 10.1517/17425247.2016.1142527. Epub 2016 Feb 6. Review.

PMID:
26785610
24.

Stability and removal of spironolactone from wastewater.

Sulaiman S, Khamis M, Nir S, Lelario F, Scrano L, Bufo SA, Karaman R.

J Environ Sci Health A Tox Hazard Subst Environ Eng. 2015;50(11):1127-35. doi: 10.1080/10934529.2015.1047668.

PMID:
26191987
25.

Stability and removal of atorvastatin, rosuvastatin and simvastatin from wastewater.

Sulaiman S, Khamis M, Nir S, Lelario F, Scrano L, Bufo SA, Mecca G, Karaman R.

Environ Technol. 2015;36(24):3232-42. doi: 10.1080/09593330.2015.1058422. Epub 2015 Jun 29.

PMID:
26047323
26.

Removal of amoxicillin and cefuroxime axetil by advanced membranes technology, activated carbon and micelle-clay complex.

Awwad M, Al-Rimawi F, Dajani KJ, Khamis M, Nir S, Karaman R.

Environ Technol. 2015 Jul-Aug;36(13-16):2069-78. doi: 10.1080/09593330.2015.1019935. Epub 2015 Mar 18.

PMID:
25686519
27.

Using predrugs to optimize drug candidates.

Karaman R.

Expert Opin Drug Discov. 2014 Dec;9(12):1405-19. doi: 10.1517/17460441.2014.954545. Epub 2014 Aug 28. Review.

PMID:
25163975
28.

Stability and removal of dexamethasone sodium phosphate from wastewater using modified clays.

Sulaimana S, Khamis M, Nir S, Lelario F, Scrano L, Bufo SA, Karaman R.

Environ Technol. 2014 Aug;35(13-16):1945-55.

PMID:
24956788
29.

Design, synthesis, and in vitro kinetics study of atenolol prodrugs for the use in aqueous formulations.

Karaman R, Qtait A, Dajani KK, Abu Lafi S.

ScientificWorldJournal. 2014 Jan 12;2014:248651. doi: 10.1155/2014/248651. eCollection 2014.

30.

Removal of Cr(VI) from aqueous environments using micelle-clay adsorption.

Qurie M, Khamis M, Manassra A, Ayyad I, Nir S, Scrano L, Bufo SA, Karaman R.

ScientificWorldJournal. 2013 Oct 3;2013:942703. doi: 10.1155/2013/942703. eCollection 2013.

31.

Computationally designed atovaquone prodrugs based on Bruice's enzyme model.

Karaman R, Fattash B, Mecca G, Bader M.

Curr Comput Aided Drug Des. 2014 Mar;10(1):15-27.

PMID:
24138416
32.

Prodrugs design based on inter- and intramolecular chemical processes.

Karaman R.

Chem Biol Drug Des. 2013 Dec;82(6):643-68. doi: 10.1111/cbdd.12224. Epub 2013 Oct 25. Review.

PMID:
23998799
33.

Efficiency of membrane technology, activated charcoal, and a micelle-clay complex for removal of the acidic pharmaceutical mefenamic acid.

Khalaf S, Al-Rimawi F, Khamis M, Nir S, Bufo SA, Scrano L, Mecca G, Karaman R.

J Environ Sci Health A Tox Hazard Subst Environ Eng. 2013;48(13):1655-62. doi: 10.1080/10934529.2013.815475.

PMID:
23947703
34.

Design, synthesis and in vitro kinetic study of tranexamic acid prodrugs for the treatment of bleeding conditions.

Karaman R, Ghareeb H, Dajani KK, Scrano L, Hallak H, Abu-Lafi S, Mecca G, Bufo SA.

J Comput Aided Mol Des. 2013 Jul;27(7):615-35. doi: 10.1007/s10822-013-9666-2. Epub 2013 Jul 24.

PMID:
23881217
35.

Computationally designed prodrugs of statins based on Kirby's enzyme model.

Karaman R, Amly W, Scrano L, Mecca G, Bufo SA.

J Mol Model. 2013 Sep;19(9):3969-82. doi: 10.1007/s00894-013-1929-2. Epub 2013 Jul 9.

PMID:
23835602
36.

Inland treatment of the brine generated from reverse osmosis advanced membrane wastewater treatment plant using epuvalisation system.

Qurie M, Abbadi J, Scrano L, Mecca G, Bufo SA, Khamis M, Karaman R.

Int J Mol Sci. 2013 Jul 3;14(7):13808-25. doi: 10.3390/ijms140713808.

37.

Efficiency of advanced wastewater treatment plant system and laboratory-scale micelle-clay filtration for the removal of ibuprofen residues.

Khalaf S, Al-Rimawi F, Khamis M, Zimmerman D, Shuali U, Nir S, Scrano L, Bufo SA, Karaman R.

J Environ Sci Health B. 2013;48(9):814-21. doi: 10.1080/03601234.2013.781372.

PMID:
23688232
38.

The future of prodrugs - design by quantum mechanics methods.

Karaman R, Fattash B, Qtait A.

Expert Opin Drug Deliv. 2013 May;10(5):713-29. doi: 10.1517/17425247.2013.786699. Epub 2013 Mar 31. Review.

PMID:
23540707
39.

Prodrugs for masking bitter taste of antibacterial drugs--a computational approach.

Karaman R.

J Mol Model. 2013 Jun;19(6):2399-412. doi: 10.1007/s00894-013-1780-5. Epub 2013 Feb 19.

PMID:
23420399
40.

Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis.

Li JZ, Huang Y, Karaman R, Ivanova PT, Brown HA, Roddy T, Castro-Perez J, Cohen JC, Hobbs HH.

J Clin Invest. 2012 Nov;122(11):4130-44.

41.

Prodrugs of fumarate esters for the treatment of psoriasis and multiple sclerosis--a computational approach.

Karaman R, Dokmak G, Bader M, Hallak H, Khamis M, Scrano L, Bufo SA.

J Mol Model. 2013 Jan;19(1):439-52. doi: 10.1007/s00894-012-1554-5. Epub 2012 Sep 2.

PMID:
22940872
42.

Removal of diclofenac potassium from wastewater using clay-micelle complex.

Karaman R, Khamis M, Quried M, Halabieh R, Makharzeh I, Manassra A, Abbadi J, Qtait A, Bufo SA, Nasser A, Nir S.

Environ Technol. 2012 Jun;33(10-12):1279-87.

PMID:
22856300
43.

Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach.

Dahan A, Khamis M, Agbaria R, Karaman R.

Expert Opin Drug Deliv. 2012 Aug;9(8):1001-13. doi: 10.1517/17425247.2012.697055. Epub 2012 Jun 18. Review.

PMID:
22703376
44.

Prodrugs of acyclovir--a computational approach.

Karaman R, Dajani KK, Qtait A, Khamis M.

Chem Biol Drug Des. 2012 May;79(5):819-34. doi: 10.1111/j.1747-0285.2012.01335.x. Epub 2012 Feb 15.

PMID:
22260647
45.

Rac signaling in osteoblastic cells is required for normal bone development but is dispensable for hematopoietic development.

Lane SW, De Vita S, Alexander KA, Karaman R, Milsom MD, Dorrance AM, Purdon A, Louis L, Bouxsein ML, Williams DA.

Blood. 2012 Jan 19;119(3):736-44. doi: 10.1182/blood-2011-07-368753. Epub 2011 Nov 28.

46.

Computational-aided design for dopamine prodrugs based on novel chemical approach.

Karaman R.

Chem Biol Drug Des. 2011 Nov;78(5):853-63. doi: 10.1111/j.1747-0285.2011.01208.x. Epub 2011 Sep 26.

PMID:
21824329
47.

Computer-assisted design for atenolol prodrugs for the use in aqueous formulations.

Karaman R, Dajani K, Hallak H.

J Mol Model. 2012 Apr;18(4):1523-40. doi: 10.1007/s00894-011-1180-7. Epub 2011 Jul 23.

PMID:
21785934
48.

Computer-assisted design for paracetamol masking bitter taste prodrugs.

Hejaz H, Karaman R, Khamis M.

J Mol Model. 2012 Jan;18(1):103-14. doi: 10.1007/s00894-011-1040-5. Epub 2011 Apr 15.

PMID:
21491187
49.

Prodrugs of aza nucleosides based on proton transfer reaction.

Karaman R.

J Comput Aided Mol Des. 2010 Dec;24(12):961-70. doi: 10.1007/s10822-010-9389-6. Epub 2010 Oct 13.

PMID:
20941527
50.

A computational analysis of intramolecularity in proton transfer reactions.

Karaman R, Pascal R.

Org Biomol Chem. 2010 Nov 21;8(22):5174-8. doi: 10.1039/c0ob00252f. Epub 2010 Sep 17.

PMID:
20848031

Supplemental Content

Loading ...
Support Center